Our Mission
To improve the lives of people impacted by hypoparathyroidism through education, support, research, and advocacy. Learn more and get involved.
NEWS & EVENTS
Unexpected manufacturing disruptions expected as early as November 21, 2020
AZP-3601 is currently in development for the treatment of hypoparathyroidism
Plans move forward with phase 3 PaTHway trial
The study will be conducted at the National Institutes of Health.
OCT 23 - 25. Live informative lectures on HypoPARA with knowledgeable doctors and specialists!
